recombinant galectin‐3 (r‐gal3 Search Results


recombinant galectin-3 (r-gal3)  (Galectin Therapeutics)
90
Galectin Therapeutics recombinant galectin-3 (r-gal3)
Recombinant Galectin 3 (R Gal3), supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant galectin-3 (r-gal3)/product/Galectin Therapeutics
Average 90 stars, based on 1 article reviews
recombinant galectin-3 (r-gal3) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
recombinant galectin 3 (r gal3  (PeproTech)
90
PeproTech recombinant galectin 3 (r gal3
Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Recombinant Galectin 3 (R Gal3, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant galectin 3 (r gal3/product/PeproTech
Average 90 stars, based on 1 article reviews
recombinant galectin 3 (r gal3 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
aid enzyme  (Recombina)
90
Recombina aid enzyme
Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Aid Enzyme, supplied by Recombina, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aid enzyme/product/Recombina
Average 90 stars, based on 1 article reviews
aid enzyme - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
recombina tion  (Recombina)
90
Recombina recombina tion
Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Recombina Tion, supplied by Recombina, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombina tion/product/Recombina
Average 90 stars, based on 1 article reviews
recombina tion - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
red-mediated recombineering  (Recombina)
90
Recombina red-mediated recombineering
Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Red Mediated Recombineering, supplied by Recombina, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/red-mediated recombineering/product/Recombina
Average 90 stars, based on 1 article reviews
red-mediated recombineering - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
recombina foxg1  (Recombina)
90
Recombina recombina foxg1
Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Recombina Foxg1, supplied by Recombina, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombina foxg1/product/Recombina
Average 90 stars, based on 1 article reviews
recombina foxg1 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
recombinant nrp-1  (Recombina)
90
Recombina recombinant nrp-1
Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Recombinant Nrp 1, supplied by Recombina, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant nrp-1/product/Recombina
Average 90 stars, based on 1 article reviews
recombinant nrp-1 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
genetic recombination  (Recombina)
90
Recombina genetic recombination
Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Genetic Recombination, supplied by Recombina, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/genetic recombination/product/Recombina
Average 90 stars, based on 1 article reviews
genetic recombination - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
line recombinant immunoblot kits recomline borrelia  (Mikrogen Diagnostik)
90
Mikrogen Diagnostik line recombinant immunoblot kits recomline borrelia
Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Line Recombinant Immunoblot Kits Recomline Borrelia, supplied by Mikrogen Diagnostik, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/line recombinant immunoblot kits recomline borrelia/product/Mikrogen Diagnostik
Average 90 stars, based on 1 article reviews
line recombinant immunoblot kits recomline borrelia - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
ess recombination  (Recombina)
90
Recombina ess recombination
Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Ess Recombination, supplied by Recombina, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ess recombination/product/Recombina
Average 90 stars, based on 1 article reviews
ess recombination - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
recombineering system  (Recombina)
90
Recombina recombineering system
Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Recombineering System, supplied by Recombina, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombineering system/product/Recombina
Average 90 stars, based on 1 article reviews
recombineering system - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cre recombina tion  (Recombina)
90
Recombina cre recombina tion
Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
Cre Recombina Tion, supplied by Recombina, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cre recombina tion/product/Recombina
Average 90 stars, based on 1 article reviews
cre recombina tion - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)

Journal: Thoracic Cancer

Article Title: Galectin‐3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2 ‐positive breast cancer cells

doi: 10.1111/1759-7714.14474

Figure Lengend Snippet: Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)

Article Snippet: Recombinant galectin‐3 (r‐Gal3) was obtained from PeproTech.

Techniques: Western Blot, Transfection